The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
Two research groups demonstrate that in Caenorhabditis elegans, behavioral traits can be passed down through the germline to future generations, even though they aren’t hard-wired.
A new study adds to the evidence that mammalian cells can use small interfering RNAs to defend against viruses, but questions remain about physiological importance.
Unwilling to accept the finality of terminal differentiation, Helen Blau has honed techniques that showcase the flexibility of cells to adopt different identities.